Professor Fraser graduated BSc and PhD from the University of Aberdeen. After a year of postdoctoral work in the National Research Council of Canada in Ottawa, he returned to the University of Aberdeen as Lecturer in Chemical Pathology. From 1975, he was Chief Clinical Biochemist at the then new Flinders Medical Centre in South Australia and Honorary Senior Lecturer in Clinical Biochemistry in the Flinders University of South Australia, later Associate Professor. He returned to Scotland in 1983 and was Director of Biochemical Medicine, NHS Tayside, and Honorary Senior Lecturer in the Universities of Dundee and St Andrews. He is currently Consultant to the Scottish Colorectal Cancer Screening Research Unit; Honorary Professor, Centre for Research into Cancer Prevention and Screening, University of Dundee, and Honorary Consultant Clinical Biochemist, NHS Tayside.

Current research interests include: Assessment of newer faecal tests in colorectal cancer screening and assessment of patients with lower abdominal symptoms: Making better use of quantitative measurements of faecal haemoglobin concentration including in risk scoring systems: Generation and application of data on biological variation

Passamonti B, Malaspina M, Fraser CG, et al. A comparative effectiveness trial of two faecal immunochemical tests for haemoglobin (FIT). Assessment of test performance and adherence in a single round of a population-based screening programme for colorectal cancer. Gut. 2016 Dec 14. pii: gutjnl-2016-312716. doi: 10.1136/gutjnl-2016-312716. [Epub ahead of print] Fraser CG. Diagnostic work-up of patients presenting in primary care with lower abdominal symptoms: which faecal test and triage strategy should be used? BMC Med 2016;14:139.. Steele RJ, Stanners G, Lang J, Brewster DH, Carey FA, Fraser CG. Interval cancers in a national colorectal cancer screening programme. United European Gastroenterol J 2016;4:587-94. Digby J, Fraser CG, Carey FA, et al. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round. J Med Screen 2016 Jul 1. pii: 0969141316653983. [Epub ahead of print] Lund F, Petersen PH, Fraser CG, S?létormos G. Different percentages of false-positive results obtained using five methods for the calculation of reference change values based on simulated normal and ln-normal distributions of data. Ann Clin Biochem 2016 53, 6:692-8. Petersen PH, Lund F, Fraser CG, S?létormos G. Analytical performance specifications for changes in assay bias (Δbias) for data with logarithmic distributions as assessed by effects on reference change values. Ann Clin Biochem. 2016;53, 6:686-91. Digby J, Fraser CG, Carey FA, Lang J, Stanners G, Steele RJ. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited. J Med Screen 2016;23:130-4. Godber IM, Todd LM, Fraser CG, MacDonald LR, Younes HB. Use of a faecal immunochemical test for haemoglobin can aid in the investigation of patients with lower abdominal symptoms. Clin Chem Lab Med 2016;54:595-602. Fraser CG, Strachan JA. A nicer approach to the use of 'faecal occult blood tests' in assessment of the symptomatic. Ann Clin Biochem 2016;53:5-6. Mowat C, Digby J, Strachan JA, Wilson R, Carey FA, Fraser CG, Steele RJ. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut. 2016;65:1463-9. Fraser CG. Assessment of faecal haemoglobin concentration distributions is vital for faecal immunochemical test (FIT)-based colorectal cancer screening programmes. J Med Screen 2016;23:52-3. Auge JM, Fraser CG, Rodriguez C, Roset A, Lopez-Ceron M, Grau J, Castells A, Jimenez W. Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. Clin Chem Lab Med. 2016;54:125-32. Mowat C, Digby J, Strachan JA, Wilson R, Carey FA, Fraser CG, Steele RJ Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut 2015 Aug 20. pii: gutjnl-2015-309579. doi: 10.1136/gutjnl-2015-309579. [Epub ahead of print] Petersen PH, Fraser CG, Lund F, S?létormos G. Confirmation of analytical performance characteristics required for the reference change value applied in patient monitoring. Scand J Clin Lab Invest. 2015 Aug 13:1-3. [Epub ahead of print] No abstract available. Fraser CG. Assessment of faecal haemoglobin concentration distributions is vital for faecal immunochemical test (FIT)-based colorectal cancer screening programmes.J Med Screen. 2015 Jul 20. pii: 0969141315597017. [Epub ahead of print] No abstract available. Auge JM, Fraser CG, Rodriguez C, Roset A, Lopez-Ceron M, Grau J, Castells A, Jimenez W. Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. Clin Chem Lab Med. 2015 Jun 27. pii: /j/cclm.ahead-of-print/cclm-2015-0388/cclm-2015-0388.xml. doi: 10.1515/cclm-2015-0388. [Epub ahead of print] Rubeca T, Cellai F, Confortini M, Fraser CG, Rapi S. Impact of preanalytical factors on fecal immunochemical tests: need for new strategies in comparison of methods. Int J Biol Markers 2015;30:e269-74. Fraser CG. The 1999 Stockholm Consensus Conference on quality specifications in laboratory medicine. Clin Chem Lab Med 2015;53:837-40. Sandberg S, Fraser CG, Horvath AR, Jansen R, Jones G, Oosterhuis W, Petersen PH, Schimmel H, Sikaris K, Panteghini M. Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2015;53(:833-5. Simundic AM, Bartlett WA, Fraser CG. Biological variation: a still evolving facet of laboratory medicine. Ann Clin Biochem 2015;52:189-90. Fraser CG, Auge JM. Faecal haemoglobin concentrations do vary across geography as well as with age and sex: ramifications for colorectal cancer screening. Clin Chem Lab Med 2015;53:e237-9. Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, Kuipers EJ, Seaman HE. Advances in Fecal Occult Blood Tests: the FIT revolution. Dig Dis Sci 2015;60:609-22. Perich C, Minchinela J, Ricós C, Fernández-Calle P, Alvarez V, Doménech MV, Simón M, Biosca C, Boned B, García-Lario JV, Cava F, Fernández-Fernández P, Fraser CG. Biological variation database: structure and criteria used for generation and update. Clin Chem Lab Med 2015;53:299-305. Simundic AM, Kackov S, Miler M, Fraser CG, Petersen PH. Terms and symbols used in studies on biological variation: the need for harmonization. Clin Chem 2015;61:438-9. Lund F, Petersen PH, Fraser CG, S?létormos G.Calculation of limits for significant bidirectional changes in two or more serial results of a biomarker based on a computer simulation model. Ann Clin Biochem. 2015;52:434-40